Private equity firm ventures into animal health; FDA declares progress in plant to cut antibiotics use;

> Private equity firm Prospect Partners has acquired Animal Emergency Specialty Center of Knoxville, TN, and turned it into a subsidiary of Innovetive Petcare, a veterinary hospital chain it recently formed. Release

> In its second progress report on its strategy to reduce the use of antibiotics in food animals, the FDA announced that 293 products are affected by new guidelines and that some manufacturers have already started making required changes. Release

> Dechra Pharmaceuticals announced that on a constant-exchange-rate basis, its sales and earnings in the last half of 2014 both increased 11% year-over-year to £101 million ($155 million) and £24.8 million ($38.2 million) respectively. Release (PDF)

> Zoetis ($ZTS) declared a second-quarter 2015 dividend of 83 cents per share. Release

> Scientists at the University of Wisconsin-Madison School of Veterinary Medicine have identified a biological mechanism by which bone tumors form--a discovery that could have implications for understanding cancer in people, too. Release

> Jaguar Animal Health has formed a supply and distribution agreement with Argentina's Biogenesis Bagó, which will have exclusive distribution rights for Neonorm Calf products in five South American countries. Release

> Kansas State University's College of Veterinary Medicine is establishing the Center for Outcomes Research and Education, with the goal of improving the effectiveness of animal health care and translating its research to human health. Release

> University of Illinois researchers are preparing to test a new cancer drug, PAC-1, in people that has proven effective in dogs with osteosarcoma and other tumor types. Release

> Purina Animal Nutrition has recalled DuMOR Sheep Formula in Florida due to higher-than-acceptable levels of copper. Release

Suggested Articles

Pfizer spinoff Zoetis met Q2 expectations and brightened its full-year forecast, but it's looking to M&A to drive further growth.

Fresenius’ new CEO has pulled off a dealmaking double play, committing more than $5.4 billion to expand its reach in both sterile generics and in biosimilars.

Bayer’s pharma products have been growing lickety-split, and its 2016 numbers show just how—and how much. But with the big Monsanto merger top of mind at Bayer…